-
Mashup Score: 0
January 2025 | ASH Clinical News | American Society of Hematology January 2025 Health Care Handcuffed? The overturning of the Chevron doctrine, a decades-old precedent, opens the door to legal challenges affecting health care agencies and, ultimately, patient care. Viewpoints Editor’s Corner Ms. Cellophane: How Clinical Research Looks Right Through People with Child-Bearing Potential Education You Make the Call You…
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0MGUS Risk Assessment Over Time Yields Benefits, Study Shows | ASH Clinical News | American Society of Hematology - 2 day(s) ago
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Using models to measure the progression risk of patients with monoclonal gammopathy of undetermined significance (MGUS) over time improves the assessment of risk of progression to smoldering multiple myeloma and multiple myeloma, according to findings published in Blood Cancer Journal. The retrospective study by a research group in Germany shows the value of regular MGUS measuring, which has become the regular practice of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Using models to measure the progression of patients with #MGUS over time improved assessment of the risk of progression to #SMM and #MMsm, with patients who were upstaged to a higher-risk category having an increased risk of progression: https://t.co/zAoDOrLkUS
-
-
Mashup Score: 1
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Patients with multiple myeloma (MM) who discontinued maintenance therapy based on measurable residual disease (MRD) negativity had a high rate of sustained MRD negativity without disease progression, according to the results of a prospective trial. The MRD2STOP study demonstrated that patients with MRD negativity at the 10 -6 threshold (less than one myeloma cell within one million cells analyzed) at the time of
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
According to the results of the prospective MRD2STOP trials, patients with #MultipleMyeloma #MM who discontinued maintenance therapy based on MRD negativity experienced a high rate of sustained MRD negativity without disease progression: https://t.co/XvZZTzPipP
-
-
Mashup Score: 0Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose | ASH Clinical News | American Society of Hematology - 10 day(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. A metronomic, low-dose schedule of decitabine and venetoclax was deemed to be a safe and effective treatment for patients with myeloid malignancies. Patients with acute myeloid leukemia (AML) who received the combination experienced a median overall survival (OS) of 16.1 months, and patients with TP53 -mutated disease had an OS of 11.3 months. Mendel Goldfinger, MD, of Montefiore Medical Center in Bronx, New York, and colleagues
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
A low-dose schedule of #decitabine and #venetoclax was found to be a safe and effective treatment for myeloid malignancies, resulting in a median OS of 16.1 months in patients with #AcuteMyeloidLeukemia and 11.3 months in those with TP53-mutated disease: https://t.co/VM2YH4KeBB
-
-
Mashup Score: 2Meletios-Thanos Dimopoulos, MD: Daratumumab Vs. Active Monitoring in High-Risk Smoldering Myeloma - 13 day(s) ago
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, interviews Meletios-Thanos Dimopoulos, MD, at the 66th ASH Annual Meeting and Exposition to discuss his ab…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Catch up on #ASH24 with ASH Clinical News! Below, @AaronGerds sat down with Dr. Meletios-Thanos Dimopoulos in San Diego to discuss the Aquila study and his findings on #daratumumab vs. active monitoring for high-risk #SmolderingMyeloma #SMM: https://t.co/5pINOvamTS
-
-
Mashup Score: 0More Work Needed to Overcome Racial, Ethnic AHCT Disparities in Multiple Myeloma | ASH Clinical News | American Society of Hematology - 14 day(s) ago
Katie Robinson is a medical writer based in New York. Autologous hematopoietic cell transplantation (AHCT) is a global standard of care for eligible patients with newly diagnosed multiple myeloma (MM), yet racial and ethnic disparities remain. According to findings published in Transplantation and Cellular Therapy, non-Hispanic Black patients had a longer time from diagnosis to AHCT and remained less likely to undergo AHCT compared with non-Hispanic white patients, though utilization rates have improved
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Despite improved #AHCT utilization rates among Black patients with #MultipleMyeloma over the last 10 years, such patients were found to have a longer time from diagnosis to AHCT and still remained less likely to undergo AHCT compared with white patients: https://t.co/N902UziaDP
-
-
Mashup Score: 1New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML | ASH Clinical News | American Society of Hematology - 16 day(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. The new AML60+ classification provides prognostic information for intensively treated patients 60 years and older with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS). The classification, available in a free online tool, is easy to apply to routine clinical practice and provides crucial information on survival after allogeneic hematopoietic cell transplantation (alloHCT). Jurjen Versluis, MD, PhD, of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Compared with previous classification systems for #AcuteMyeloidLeukemia, the new AML60+ classification provides improved prognostic information for older patients and could identify those who would benefit from intensive #chemotherapy and #alloHCT: https://t.co/Y2n1AWk2vc
-
-
Mashup Score: 2
ASH Clinical News Deputy Editor Bethany Samuelson Bannow, MD, interviews Anne de Vaan, MD, PhD candidate, at the 66th ASH Annual Meeting and Exposition to di…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
At #ASH24, @bsamuelson_md caught up with Dr. Anne de Vaan to discuss her research on #postpartum #hemorrhage in #hemophilia A and B carriers following enhanced prophylactic clotting factor suppletion. Check out their conversation below! https://t.co/YJiSuVvy3V
-
-
Mashup Score: 3David John Lewis, MD: Ibrutinib and Rituximab in Older Patients with Mantle Cell Lymphoma - 24 day(s) ago
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, interviews David John Lewis, MD, at the 66th ASH Annual Meeting and Exposition to discuss his abstract on …
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Catch on some of the groundbreaking research from #ASH24! Below, @AaronGerds sits down with Dr. David John Lewis to discuss his abstract on the use of #ibrutinib and #rituximab in in older patients with previously untreated #MantleCellLymphoma: https://t.co/73UB17nAYD
-
-
Mashup Score: 5BOVen Regimen NCCN-Approved Option for TP53-Mutated MCL | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. The three-drug regimen of zanubrutinib, obinutuzumab, and venetoclax—dubbed the BOVen regimen—is an effective option for patients with TP53 -mutated mantle cell lymphoma (MCL), according to results of a phase II study published in Blood. 1 This “chemo-free” regimen combining a BTK inhibitor, BCL2 inhibitor, and an anti-CD20 monoclonal antibody yielded a high overall response rate (ORR), high rates of complete response (CR), and a
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
The three-drug regimen of #zanubrutinib, #obinutuzumab, and #venetoclax was found to be an effective option for patients with TP53-mutated #MantleCellLymphoma, with an ORR of 96% and CR of 88%: https://t.co/Sbdp8HsDv7
-
Our January issue is out now! In addition to recap from #ASH24, highlights of this issue include articles on the overturning of the #Chevron doctrine, post-transplant BKV-related #hemorrhagic #cystitis in children, and more. Check out the full lineup at https://t.co/5uwagK7UBq https://t.co/0evBI7IfX8